AU2019219004B2 - Treatment of ophthalmologic diseases - Google Patents

Treatment of ophthalmologic diseases Download PDF

Info

Publication number
AU2019219004B2
AU2019219004B2 AU2019219004A AU2019219004A AU2019219004B2 AU 2019219004 B2 AU2019219004 B2 AU 2019219004B2 AU 2019219004 A AU2019219004 A AU 2019219004A AU 2019219004 A AU2019219004 A AU 2019219004A AU 2019219004 B2 AU2019219004 B2 AU 2019219004B2
Authority
AU
Australia
Prior art keywords
weeks
ser
treatment
vegf
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019219004A
Other languages
English (en)
Other versions
AU2019219004A1 (en
Inventor
Aaron Osborne
Jayashree SAHNI
Robert James Weikert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Genentech Inc
Original Assignee
F Hoffmann La Roche AG
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG, Genentech Inc filed Critical F Hoffmann La Roche AG
Publication of AU2019219004A1 publication Critical patent/AU2019219004A1/en
Application granted granted Critical
Publication of AU2019219004B2 publication Critical patent/AU2019219004B2/en
Priority to AU2025220842A priority Critical patent/AU2025220842A1/en
Priority to AU2025220841A priority patent/AU2025220841A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2019219004A 2018-02-06 2019-02-05 Treatment of ophthalmologic diseases Active AU2019219004B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2025220842A AU2025220842A1 (en) 2018-02-06 2025-08-22 Treatment of ophthalmologic diseases
AU2025220841A AU2025220841A1 (en) 2018-02-06 2025-08-22 Treatment of ophthalmologic diseases

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862627103P 2018-02-06 2018-02-06
US62/627,103 2018-02-06
US201862729333P 2018-09-10 2018-09-10
US62/729,333 2018-09-10
PCT/EP2019/052704 WO2019154776A1 (en) 2018-02-06 2019-02-05 Treatment of ophthalmologic diseases

Related Child Applications (2)

Application Number Title Priority Date Filing Date
AU2025220842A Division AU2025220842A1 (en) 2018-02-06 2025-08-22 Treatment of ophthalmologic diseases
AU2025220841A Division AU2025220841A1 (en) 2018-02-06 2025-08-22 Treatment of ophthalmologic diseases

Publications (2)

Publication Number Publication Date
AU2019219004A1 AU2019219004A1 (en) 2020-07-16
AU2019219004B2 true AU2019219004B2 (en) 2025-06-05

Family

ID=65352014

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2019219004A Active AU2019219004B2 (en) 2018-02-06 2019-02-05 Treatment of ophthalmologic diseases
AU2025220842A Pending AU2025220842A1 (en) 2018-02-06 2025-08-22 Treatment of ophthalmologic diseases
AU2025220841A Pending AU2025220841A1 (en) 2018-02-06 2025-08-22 Treatment of ophthalmologic diseases

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2025220842A Pending AU2025220842A1 (en) 2018-02-06 2025-08-22 Treatment of ophthalmologic diseases
AU2025220841A Pending AU2025220841A1 (en) 2018-02-06 2025-08-22 Treatment of ophthalmologic diseases

Country Status (12)

Country Link
US (2) US20210139576A1 (enExample)
EP (1) EP3749359A1 (enExample)
JP (5) JP7005772B2 (enExample)
KR (3) KR20250166355A (enExample)
CN (4) CN119909169A (enExample)
AU (3) AU2019219004B2 (enExample)
CA (1) CA3088355A1 (enExample)
IL (1) IL276383B2 (enExample)
MX (1) MX2020007527A (enExample)
SG (1) SG11202006712XA (enExample)
TW (3) TW202535932A (enExample)
WO (1) WO2019154776A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2017117464A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
US11524053B2 (en) 2018-01-26 2022-12-13 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents
BR112020017872A2 (pt) 2018-03-02 2020-12-22 Kodiak Sciences Inc. Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos
EP4010370A1 (en) * 2019-08-06 2022-06-15 F. Hoffmann-La Roche AG Personalized treatment of ophthalmologic diseases
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
IL293131A (en) 2019-11-25 2022-07-01 Univ California Long-acting vegf inhibitors for intraocular neovascularization
CR20230114A (es) * 2020-09-04 2023-05-18 Hoffmann La Roche Anticuerpo que se une a vegf-a y ang2, y métodos de uso
WO2022057888A1 (zh) * 2020-09-17 2022-03-24 江苏恒瑞医药股份有限公司 特异性结合vegf和ang-2的双特异性抗原结合分子
EP4313148A4 (en) * 2021-03-30 2025-02-19 Abpro Corporation METHODS FOR TREATING CHOROIDAL NEOVASCULARIZATION WITH MULTI-SPECIFIC ANTI-ANG2 X VEGF ANTIBODIES
JP2024515220A (ja) 2021-04-26 2024-04-05 セラニーズ・イーブイエイ・パフォーマンス・ポリマーズ・エルエルシー 高分子薬剤化合物の持続放出用の埋め込み型デバイス
CN118139628A (zh) * 2021-08-23 2024-06-04 阿维麦克思生物制药公司 用于转基因表达的组合物和方法
CN117100845A (zh) * 2022-10-24 2023-11-24 景泽生物医药(合肥)股份有限公司 重组人奥克纤溶酶在制备治疗脉络膜血管疾病药物中的用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
ES2236634T3 (es) 1997-04-07 2005-07-16 Genentech, Inc. Anticuerpos anti-vegf.
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
JP5620626B2 (ja) 2005-03-31 2014-11-05 中外製薬株式会社 会合制御によるポリペプチド製造方法
WO2007110205A2 (en) 2006-03-24 2007-10-04 Merck Patent Gmbh Engineered heterodimeric protein domains
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
PT2235064E (pt) 2008-01-07 2016-03-01 Amgen Inc Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
CN102459346B (zh) 2009-04-27 2016-10-26 昂考梅德药品有限公司 制造异源多聚体分子的方法
EP2519544A1 (en) 2009-12-29 2012-11-07 Emergent Product Development Seattle, LLC Polypeptide heterodimers and uses thereof
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
EP2569337A1 (en) 2010-05-14 2013-03-20 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
RU2604490C2 (ru) 2010-11-05 2016-12-10 Займворкс Инк. ДИЗАЙН УСТОЙЧИВОГО ГЕТЕРОДИМЕРНОГО АНТИТЕЛА С МУТАЦИЯМИ В Fc ДОМЕНЕ
MX385629B (es) * 2011-01-13 2025-03-18 Regeneron Pharma Uso de un antagonista de factor de crecimiento endotelial vascular para tratar trastornos oculares angiogenicos.
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
PL2794905T3 (pl) 2011-12-20 2020-11-02 Medimmune, Llc Zmodyfikowane polipeptydy dla rusztowań przeciwciał dwuswoistych
ES2743399T3 (es) 2012-04-20 2020-02-19 Merus Nv Métodos y medios para la producción de moléculas heterodiméricas similares a Ig
SG11201408538PA (en) 2012-07-13 2015-02-27 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
PL2887958T3 (pl) * 2012-08-21 2021-11-22 Opko Pharmaceuticals, Llc Formulacje liposomowe
KR102266819B1 (ko) * 2013-04-29 2021-06-18 에프. 호프만-라 로슈 아게 Fc-수용체 결합 개질된 비대칭 항체 및 이의 사용 방법
KR20150063728A (ko) 2013-12-02 2015-06-10 삼성전자주식회사 항 VEGF-C/항 Ang2 이중 특이 항체
TWI705827B (zh) * 2014-11-07 2020-10-01 瑞士商諾華公司 治療眼部疾病之方法
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
HRP20220066T1 (hr) * 2014-12-11 2022-04-15 Bayer Healthcare Llc Liječenje makularne degeneracije povezane sa starenjem s malom aktivnom koroidnom neovaskularizacijskom lezijom
AR103477A1 (es) * 2015-01-28 2017-05-10 Lilly Co Eli Compuestos de vegfa / ang2
US10654922B2 (en) * 2016-05-13 2020-05-19 Askgene Pharma Inc. Angiopoietin 2, VEGF dual antagonists
EP3472177B1 (en) * 2016-06-17 2024-08-14 F. Hoffmann-La Roche AG Purification of multispecific antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHAKRAVARTHY U: OPHTHALMOLOGY RETINA 20171101 ELSEVIER INC USA, vol. 1, no. 6, 1 November 2017 (2017-11-01), pages 474 - 485, XP002790566, ISSN: 2468-6530 *

Also Published As

Publication number Publication date
KR20250166355A (ko) 2025-11-27
JP7273204B2 (ja) 2023-05-12
CN111699004A (zh) 2020-09-22
CA3088355A1 (en) 2019-08-15
MX2020007527A (es) 2020-09-09
TWI885720B (zh) 2025-06-01
JP7646727B2 (ja) 2025-03-17
AU2019219004A1 (en) 2020-07-16
SG11202006712XA (en) 2020-08-28
AU2025220842A1 (en) 2025-09-11
KR20200119274A (ko) 2020-10-19
TW202419464A (zh) 2024-05-16
JP2021506947A (ja) 2021-02-22
TW202535932A (zh) 2025-09-16
EP3749359A1 (en) 2020-12-16
IL276383B2 (en) 2024-01-01
JP2023099094A (ja) 2023-07-11
TWI831764B (zh) 2024-02-11
US20210139576A1 (en) 2021-05-13
IL276383B1 (en) 2023-09-01
AU2025220841A1 (en) 2025-09-11
JP2022046738A (ja) 2022-03-23
JP2025084977A (ja) 2025-06-03
US20230416353A1 (en) 2023-12-28
TW202000700A (zh) 2020-01-01
WO2019154776A1 (en) 2019-08-15
KR20240093772A (ko) 2024-06-24
CN119909169A (zh) 2025-05-02
JP7005772B2 (ja) 2022-02-10
JP2025084976A (ja) 2025-06-03
CN119770646A (zh) 2025-04-08
CN119733046A (zh) 2025-04-01
IL276383A (en) 2020-09-30

Similar Documents

Publication Publication Date Title
AU2019219004B2 (en) Treatment of ophthalmologic diseases
EP2729172B1 (en) Antibodies against epidermal growth factor receptor (egfr) and uses thereof
AU2019370601B2 (en) Antibody formulation
TWI881273B (zh) 眼科疾病之個人化治療
JP2008508881A (ja) Ｄｋｋ−１に対する抗体
AU2016348418B2 (en) Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using same
CN101443042A (zh) Il-1抗体用于治疗眼疾病的用途
AU2021272212B2 (en) Formulation comprising anti-il-23p19 antibody, method for preparing same and use thereof
WO2023125485A9 (en) TrkB ANTIBODY AND APPLICATION THEREOF
TW202426494A (zh) 預測對ｉｌ－６拮抗劑的反應
HK40034720A (zh) 眼科疾病的治疗
HK40065038A (en) Personalized treatment of ophthalmologic diseases

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)